Post reply

Reply to the message by David Turell

Name:

E-mail: (optional, won't be displayed directly)

Leave this field empty:

Homepage: (optional)

Leave this field empty:

Location: (optional)

Remember me (cookie)

Category:

Subject:

Formatting help

skip to input

format text bold: [b]bold text[/b]
format text italic: [i]italic text[/i]
insert hyperlink: [link=http://example.com/]link text[/link] / [link]http://example.com/[/link]
set text color: [color=#rgb]colored text[/color]
font size: [size=small]small text[/size]; [size=large]large text[/size]
insert list: [list][*]list item[/list]
insert image: [img]http://example.com/image.jpg[/img]; left: [img=left]http://example.com/image.jpg[/img]; right: [img=right]http://example.com/image.jpg[/img]; thumbnail: [img=thumbnail]http://example.com/image.jpg[/img]; thumbnail left: [img=thumbnail-left]http://example.com/image.jpg[/img]; thumbnail right: [img=thumbnail-right]http://example.com/image.jpg[/img]

:-)
;-)
:-P
:-D
:-|
:-(

Message:

> HI V severely  damages both T and B cells, and requires antiviral drugs to treat. Thev rticole covers manipulations to try to develop vaccines:
> 
> https://medicalxpress.com/news/2020-06-adjuvant-successful-immunity-hiv.html
> 
> "Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV. 
> 
> "In this pre-clinical study that included 90 rhesus monkeys, the researchers showed 3M-052, a new, synthetic small molecule that targets a specific receptor (TLR 7/8), successfully induced vaccine-specific, long-lived bone marrow plasma cells (BM-LLPCs), which are critical for durable immunity. In a striking observation, 3M-052-induced BM-LLPCs were maintained at high numbers for more than one year after vaccination. This prolonged interval is not only feasible in monitoring pre-clinical effectiveness, it is also highly informative in down selecting vaccine candidates.
> 
> "First author Sudhir Pai Kasturi, Ph.D., an assistant professor in the Department of Pathology and Laboratory Medicine and a research assistant professor at Yerkes and the EVC, says, "We have known adjuvants are critical immunity-boosting supplements that help improve the effectiveness of vaccines. Until now, however, it has been unclear which class of adjuvants can promote stable and long-lived immunity in nonhuman primate models. Our study provides that information."
> 
> "Co-senior author Rafi Ahmed, Ph.D., director of the Emory Vaccine Center, adds, "The key to a successful vaccine is durability of immune responses. Antibodies provide the first line of defense against pathogens, and antibody levels are maintained by the generation of long-lived plasma cells that reside in bone marrow. Our study identifies an adjuvant that is effective in generating such long-lived plasma cells in bone marrow. This finding has implications for developing successful vaccines against HIV, influenza and, especially important now, COVID-19."
> 
> Comment: Avoiding B an T cells and using plasma cells, another line of defense, is a clever approach. A constant stream of antibodies must be produced to cure HIV. So far,  none